Hematopoietic stem cell transplantation for acquired aplastic anemia in 2024: Report from the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG)
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Lanping Xu und 26 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Anemia, Aplastic, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Peking University, National Key Research and Development Program of China.
Abstract (Originalsprache)
Allogeneic hematopoietic stem cell transplantation (HCT) is a curative treatment for acquired aplastic anemia (AA). More than 1000 cases of transplants for AA are performed annually in China, and transplant protocols have been continuously refined over recent years. To characterize contemporary transplant practices in China and provide useful insights for global professionals, this study analyzed the 2024 Chinese National Registry data. In 2024, 1919 transplants were reported among 1893 patients by 158 centers. Haploidentical donor (HID) was the leading donor source (57.22%). Matched sibling donor (MSD) and unrelated donor (URD) were used in 19.23% and 17.87% of cases, respectively. The G-CSF/ATG-based platform (84.42%) was the predominant transplant modality, followed by the ATG/ATLG + PTCY platform (14.17%). Low-dose busulfan was frequently used in conditioning regimens for both platforms. Due to the dominant use of HID and peripheral blood stem cell grafts, novel graft-versus-host disease (GVHD) prophylactic strategies have been explored. Based on a representative contemporary cohort of 226 patients, we report a favorable 1-year survival rate of 92.0% and a GVHD-/failure-free survival rate of 77.8%, which are comparable to reports from the EBMT and CIBMTR. Moreover, modern HCT practice supports broader consideration of transplantation for older patients, especially those aged 40-50 years. In conclusion, our report offers a comprehensive overview of the current HCT landscape in China and serves as a valuable resource for global practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chin…
- State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sc…
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, Guangdong, China.
- Hebei Yanda Lu Daopei Hospital, Langfang, Hebei & Beijing Lu Daopei Hospital, Beijing, China.
- Children's Hospital of Soochow University, Suzhou, Jiangsu, China.
Förderung
- Peking University
- National Key Research and Development Program of China
Zitieren
APA
Xu, L., Lin, F., Jiang, E., Bian, Z., Wang, S., Lu, Y., Hu, S., Wang, H., Zhang, Y., Luo, C., Miao, M., Zhu, X., Ye, B., Wang, X., Xia, L., Fu, Y., Xu, Y., Wu, R., Mao, Y., …, & CBMTRG (2026). Hematopoietic stem cell transplantation for acquired aplastic anemia in 2024: Report from the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG). Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218854
Vancouver
Xu L, Lin F, Jiang E, Bian Z, Wang S, Lu Y, et al. Hematopoietic stem cell transplantation for acquired aplastic anemia in 2024: Report from the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG). Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218854
BibTeX
@article{Xu2026,
author = {Xu, Lanping and Lin, Fan and Jiang, Erlie and Bian, Zhilei and Wang, Shunqing and Lu, Yue and Hu, Shaoyan and Wang, Hongmei and Zhang, Yicheng and Luo, Chengjuan and Miao, Miao and Zhu, Xiaoyu and Ye, Baodong and Wang, Xianjing and Xia, Linghui and Fu, Yuewen and Xu, Yajing and Wu, Runhui and Mao, Yanna and Liu, Daihong and Ding, Li and Gao, Ju and Huang, Ke and Zhou, Fang and Zhang, Xiaohui and Huang, Xiaojun and CBMTRG, CBMTRG},
title = {Hematopoietic stem cell transplantation for acquired aplastic anemia in 2024: Report from the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG)},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218854}
}
EUVIMED